Thirty healthy individuals as well as 42 patients with coronary artery disease (CAD) verified by coronary angiography were examined before and 6 month after percutaneus transluminal coronary angioplasty followed by stent implantation and statins treatment. Such therapy positively influenced high sensitivity C-reactive protein, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol concentration in blood scrum as well as cholesterol to phospholipid ratio. By contrast, scrum concentration of neopterin, total homocysteine, pyridoxal-5-phosphate, triglycerol and phospholipids as well as fatty acid content of phospholipids remained unchanged or became worse. These changes were followed by restenosis or new coronary events in half of observed CAD patients. Findings suggest that cholesterol concentration has no pivotal role, neither in restenosis nor in the development of coronary events after stent implantation. Elevated serum concentration of neopterin and homocysteine before and 6 months after stent implantation appear more significant indicator of new coronary events in CAD patients. Further investigations arc necessary to substantiate these observations.
Introduction
men and 12 women, aged 42-81 years), verified by coronary angiography ( 1 -artery disease: 23 patients; 2-Indices of inflammation such as C-reactive protein or 3-artcry disease: 19 patients) were included in this (CRP) and neopterin (1) (2) (3) (4) (5) , as well as homocysteine (6- study. Among CAD patients, 9 had diabetes and 8 had 8), pyridoxal-5-phosphate (P-5-P) (9) and lipids: total slight renal complications. All 26 patients received cholesterol, high density lipoprotein cholesterol treatment with statins (Zocor or Sortis, 10-20 mg/day). (HDL), low density lipoprotein cholesterol (LDL).
Neopterin (BRAHMS. Berlin, Germany), homocystriglycerides, phospholipids, fatty acid content of teine (Abbot IMx), high sensitivity CRP (hsCRP), phospholipids and cholesterol to phospholipid ratio triglycerides, cholesterol, and HDL (Dade Behring) (CHOL/PL) (10) (11) (12) (13) (14) (15) are acknowledged as risk factors were measured by comercially available immunoasin the development and progression of coronary artery says according to manufacturers' instructions. If disease (CAD). The aim of this study was to examine triglycerides concentration was below 6 mmol/L, LDL and to evaluate above-mentioned indices in healthy concentration was calculated using Friedewald formuindividuals as well as in CAD patients before and 6 la. Serum P-5-P concentration was measured by the months after percutaneus transluminal coronary angiomethod of Serfontein and others (9) . After extraction plasty (PTCA) followed by stent implantation.
of lipids by Folch and others (16) , the method of Urbach and Raabe was used to determine phospholipids concentration (17) . acid methyl esters was applied: helium was used as carrier gas, and the sorbent was chromosorb covered with DEAG. The distribution of fatty acid methylesters was obtained at 2 10°C using flame ionisation detection with adequate speed of helium.
Statistical analyses
The statistical significance of differences between results obtained in healthy individuals and in CAD patients as well as between patients before coronary angioplasty and 6 month after coronary angioplasty followed by stent implantation was calculated using the Student's t-test. Ρ values below 0.05 were considered to indicate significant differences. and unsaturated fatty acid content of phospholipids were lowered in patients compared to the controls (Table 1 ) .
Six months after PTCA and stent implantation, a major part of CAD patients was also treated with statins, serum concentration of hsCRP, cholesterol, HDL. LDL, and CHOL/PL declined (Table 2 ), but the concentrations of all other parameters remained unchanged or even took a turn to the worse (Fig. 1 ) . During follow-up of patients, changes were followed by restenosis in 17 patients or new coronary events in 4 patients, which corresponds to approximately 50% of patients who presneted with progression of CAD. Table 1 shows the indi ces of inflammation (hsCRP, neopterin) and other risk factors in healthy individuals and in patients with CAD before PTCA. Compared to healthy controls, higher serum concentrations of hsCRP, neopterin, homocysteine, triglycerides, cholesterol, HDL and LDL were observed, as well as the ratio CHOL/PL and the percentage of palmitic and stearic acid content of phospholipids was higher in patients with CAD verified by coronary angiography. By contrast, P-5-P and phospholipids concentrations Our measurements of triglycerides, cholesterol, HDL and LDL cholesterol as well as CHOL/PL in CAD patients agree well with data in literature on patients with atherosclerosis, ishemic heart disease and essential hypertension (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . The deviations of serum phospholipids concentration as well as fatty acid content of phospholipids also agree with results of our previous investigations in patients with ischemic heart disease, atherosclerosis and essential hypertension (28, 29) , as well as in cardiovascular patients with activated immune system, e.g. dilated cardiomyopathy (14) . The profound decrease of P-5-P and increase of hsCRP, neopterin and homocysteine serum concentra- Figure I . High sensitivity C-reactive protein, neopterin, homocysteine and pyridoxal-5-phosphate concentrations in sera of patients with coronary artery disease before (white columns) and 6 months after (black columns) percutaneus transluminal coronary angioplasty followed by stent implantation and treatment with statins; left part shows results obtained in patients with good response to therapy, right part shows patients with restenosis or new events during 6 months of follow-up. Mean values ± S.D. are shown, *p<0.05 (paired test) tions in CAD patients before PTCA found in this study agrees with data of our previous investigations (30,3 1 ) . All patients of this study were treated by stent implantation and the majority of them received statins. After 6 months, effects of this treatment have been evaluated by coronary angiography and repeated determination of all biochemical indices.
Discussion

Results
The hypolipidemic effect of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) has been investigated since 1987. These drugs arc used for the treatment of hypercholesterolemia (21, 33) , and clinical trials have demonstrated that they can induce regression of vascular atherosclerosis as well as reduce cardiovascular morbidity and mortality in patients with CAD and other cardiovascular diseases (21, 32, 34, 35) . Slight and/or statistically significant decrease of cholesterol, HDL and LDL as well as CHOL/PL observed 6 months after the treatment partly agrees with data in literature. Unfortunately restenosis or new coronary events, which were found in approximately 50% of repeatedly examined patients, suggest that cholesterol-lowering treatment by statins did not prevent morbidity in these cases. Moreover, serum concentration of neopterin, homocysteine, P-5-P, triglycerides, phopholipids as well as fatty acid content of phopholipids remained unchanged or even further deteriorated. Therefore, despite of the data in the literature that statins may have a direct anti-inflammatory effect on monocytes and macrophages via a decreasing the expression of, e.g., intercellular adhesion molecule-1 (36) and of lipopolysacchande-induced secretion of interleukin-6 (37, 38) , results of our study show only normalisation of hsCRP in serum that is produced neither by monocytes nor by macrophages. Human macrophages produce neopterin, mean concentration of which is elevated in blood serum of CAD patients cither before PTCA or 6 months after PTCA, followed by both, stent implantation and begin of treatment with statins. It is mentioned in the literature that elevated neopterin concentration predicts adverse events in patients with non Q-wave myocardial infarction (39) . Macrophages as well as smooth muele cells are localised in intima of blood vessel wall. Average homocysteine concentration is slightly elevated in blood scrum of CAD patients either before PTCA or 6 months after PTCA, and homocysteine may stimulate endothelial and smooth muscle cell growth of blood vessels (6, 7) . Elevated serum concentrations of neopterin and homocysteine seem to predict either restenosis or new coronary events in patients with CAD. Importantly, also homocysteine was found to be released in incerased amounts from stimulated peripheral blood mononuclear cells (40) . Data indicate that immune activation and inflammation could underly increase of homocysteine in CAD patients. Further investigations are necessary to clarify the exact relationships in patients.
